Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lingmin Zeng

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 8, 2025
Berberine is a Novel Mitochondrial Calcium Uniporter Inhibitor that Disrupts MCU-EMRE AssemblyHaixin Zhao, Siqi Chen, Nian Cao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.
The New England Journal of Medicine|September 21, 2020
Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung CancerYi-Long Wu, Masahiro Tsuboi, Jie He, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 8, 2025
Berberine is a Novel Mitochondrial Calcium Uniporter Inhibitor that Disrupts MCU-EMRE AssemblyHaixin Zhao, Siqi Chen, Nian Cao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.
The New England Journal of Medicine|September 21, 2020
Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung CancerYi-Long Wu, Masahiro Tsuboi, Jie He, et al.
Pageof 2